News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orgenesis and ATMI Enter Into Process Development Agreement


5/9/2013 9:33:18 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel and WHITE PLAINS, N.Y., May 9, 2013 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that its wholly owned subsidiary, Orgenesis Ltd., has entered into a process development agreement (the "PD Agreement") with ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
ATMI
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES